Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report report published on Sunday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ:ADXS opened at $0.02 on Friday. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49. The stock has a market cap of $852,660.00, a P/E ratio of 0.00 and a beta of 1.51. The firm has a fifty day moving average price of $0.05 and a 200 day moving average price of $0.31.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.